Many people with psoriatic arthritis focus on joint pain and skin flare-ups. They may not realize their lungs could be at risk too. A new review shows that a hidden lung problem is more common than doctors once thought.
This lung condition is called interstitial lung disease, or ILD. It causes scarring in the tissue between the air sacs. Over time, that scarring can make breathing harder. The new analysis suggests this issue affects a meaningful number of people with psoriatic arthritis.
Psoriatic arthritis is a chronic inflammatory disease that affects the joints and skin. It can also affect tendons and the spine. Millions of adults live with this condition worldwide. Current care focuses on joint symptoms and skin plaques. Lung health often gets less attention during routine visits.
Many patients and even some doctors may not link arthritis with lung trouble. That can lead to missed diagnoses. Early detection matters because lung scarring can progress silently. When caught early, doctors can adjust treatment and reduce risk factors.
But here is the twist. Doctors have not classically viewed lung disease as a core part of psoriatic arthritis. That view may be changing. New evidence suggests lung involvement is more common than previously recognized.
The old way of thinking was to look for lung problems only when symptoms appear. The new way is to consider screening for lung disease even in people without obvious breathing issues. This shift could help catch problems earlier.
The lungs have a delicate structure that can be damaged by chronic inflammation. Think of the lung tissue like a fine mesh net. Inflammation can cause thick scars to form, like patches of glue on the net. Those scars make the net less flexible and harder for air to pass through.
In psoriatic arthritis, the immune system is overactive. It can attack the joints and skin. It may also attack the lungs. This shared immune pathway could explain why lung scarring appears in some patients. Smoking adds fuel to the fire by irritating the lungs and increasing inflammation.
The researchers conducted a systematic review and meta-analysis. They registered the study protocol in PROSPERO, a research database. They searched major medical databases from their start dates through January 2026. They included observational studies that reported ILD prevalence in psoriatic arthritis patients.
They pooled data from six studies that included 14,272 patients. They used statistical models to combine the results. They also ran subgroup analyses based on how doctors diagnosed ILD. This approach helps provide a clearer picture of the true burden.
The pooled prevalence of ILD was 3 percent. That means about 3 out of every 100 patients with psoriatic arthritis had ILD. The confidence interval ranged from 1 percent to 7 percent. This range reflects uncertainty due to differences across studies.
Prevalence was higher when doctors used imaging to diagnose ILD. Studies using computed tomography or high-resolution computed tomography found about 6 percent prevalence. Studies that did not use imaging found about 1 percent. The difference between these groups was statistically significant.
This finding suggests imaging can uncover lung disease that might otherwise be missed. It also shows that how doctors look for ILD changes how common it appears. That does not mean every patient needs a scan. It does mean awareness and careful evaluation are important.
Smoking was linked to a significantly increased risk of ILD in psoriatic arthritis. The pooled odds ratio was about 2.94. In plain terms, smoking roughly tripled the odds of having ILD compared with not smoking. This is a strong and consistent signal.
This does not mean every patient with psoriatic arthritis has lung disease.
Experts in rheumatology and pulmonology have long noted that lung problems can occur with autoimmune diseases. This review adds specific numbers for psoriatic arthritis. It also highlights the role of imaging and the impact of smoking. Clinicians may consider more proactive screening in high-risk patients.
What this means for you is straightforward. If you have psoriatic arthritis, talk with your doctor about lung health. Mention any new cough, shortness of breath, or reduced exercise tolerance. Ask whether imaging or other tests are appropriate based on your risk factors. If you smoke, quitting is one of the most effective steps to protect your lungs.
The review has limitations. The number of included studies was small. The overall heterogeneity was high, meaning results varied across studies. Not all studies used the same methods to diagnose ILD. These factors can affect the precision of the estimates.
Future research should focus on prospective studies that follow patients over time. Standardized screening protocols would help compare results across centers. Larger studies could also explore how different treatments for psoriatic arthritis affect lung health. Ongoing trials may provide more guidance on the best ways to detect and manage ILD early.
Researchers are also exploring whether certain biomarkers in the blood can signal lung involvement. If validated, these markers could help doctors decide who needs imaging. For now, increased awareness and careful evaluation remain the best tools. As more data emerge, screening guidelines may evolve to include routine lung assessment for people with psoriatic arthritis.